"Adrenocortical Carcinoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
| Descriptor ID |
D018268
|
| MeSH Number(s) |
C04.557.470.200.025.152 C04.588.322.078.265.750 C19.053.098.265.750 C19.053.347.500.750 C19.344.078.265.750
|
| Concept/Terms |
Adrenocortical Carcinoma- Adrenocortical Carcinoma
- Adrenocortical Carcinomas
- Carcinomas, Adrenocortical
- Carcinoma, Adrenocortical
- Carcinoma, Adrenal Cortical
- Adrenal Cortical Carcinoma
- Adrenal Cortical Carcinomas
- Carcinomas, Adrenal Cortical
|
Below are MeSH descriptors whose meaning is more general than "Adrenocortical Carcinoma".
Below are MeSH descriptors whose meaning is more specific than "Adrenocortical Carcinoma".
This graph shows the total number of publications written about "Adrenocortical Carcinoma" by people in this website by year, and whether "Adrenocortical Carcinoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2022 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenocortical Carcinoma" by people in Profiles.
-
Treatment Differences for Adrenocortical Carcinoma by Race and Insurance Status. J Surg Res. 2022 12; 280:169-178.
-
Treatment differences at high volume centers and low volume centers IN NON -metastatic and metastatic adrenocortical carcinoma. Am J Surg. 2022 03; 223(3):587-588.
-
Treatment differences at high volume centers and low volume centers in non-metastatic and metastatic adrenocortical carcinoma. Am J Surg. 2022 03; 223(3):582-586.
-
Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma. J Surg Res. 2020 12; 256:90-95.
-
Risk factors associated with positive resection margins in patients with adrenocortical carcinoma. Am J Surg. 2020 10; 220(4):932-937.
-
National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress? J Clin Endocrinol Metab. 2019 12 01; 104(12):5948-5956.
-
Expression of programmed death ligand 1 and 2 in adrenocortical cancer tissues: An exploratory study. Surgery. 2019 01; 165(1):196-201.
-
Minimally Invasive Adrenalectomy for Adrenocortical Carcinoma: Five-Year Trends and Predictors of Conversion. World J Surg. 2018 02; 42(2):473-481.
-
Preoperative adrenal biopsy does not affect overall survival in adrenocortical carcinoma. Am J Surg. 2017 Oct; 214(4):748-751.
-
The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm Cancer. 2014 Aug; 5(4):232-9.